New hope for Tough-to-Treat digestive tumors
NCT ID NCT03891784
Summary
This study is testing whether the drug abemaciclib can help control advanced digestive system neuroendocrine tumors that have spread and stopped responding to standard treatments. The drug works by blocking enzymes that tumor cells need to grow. About 20 patients with these specific tumors will take the drug orally twice daily to see if it shrinks their tumors or slows their progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
University of Colorado
Denver, Colorado, 80217, United States
Conditions
Explore the condition pages connected to this study.